PALLAVI VELAGAPUDI
MIAMI BEACH, FL NPI 1699418178
Browse related groups: FL ABBVIE INC. All categories
General Payments — all program years on this page
$610.00
- Category: General Payments
- Program years: PY2023–2024
- Record count: 11
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $544.14 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $544.14 | 8 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $187.20 | 3 |
| Amgen Inc. | $149.90 | 1 |
| GENZYME CORPORATION | $119.71 | 1 |
| Actelion Pharmaceuticals US, Inc. | $36.88 | 1 |
| GlaxoSmithKline, LLC. | $35.82 | 1 |
| Janssen Pharmaceuticals, Inc | $14.63 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1077969310 | Janssen Pharmaceuticals, Inc | $14.63 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1078877906 | Actelion Pharmaceuticals US, Inc. | $36.88 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1106277292 | ABBVIE INC. | $123.50 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1106277294 | ABBVIE INC. | $29.80 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1106277296 | ABBVIE INC. | $33.90 | 12/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1116586277 | GlaxoSmithKline, LLC. | $35.82 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1117708780 | Amgen Inc. | $149.90 | 07/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1139989977 | GENZYME CORPORATION | $119.71 | 07/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.